# OnCo record high-risk-gtn (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/high-risk-gtn/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "high-risk-gtn" ;
  schema:name "High-risk gestational trophoblastic neoplasia (FIGO score 7 or more, including ultra-high-risk)"@en ;
  schema:alternateName "High-risk GTN"@en, "Metastatic gestational choriocarcinoma"@en, "Ultra-high-risk gestational trophoblastic neoplasia (score 13 or more)"@en, "Choriocarcinoma after term pregnancy"@en ;
  schema:description "High-risk gestational trophoblastic neoplasia is the aggressive form of this pregnancy-related cancer, usually choriocarcinoma that has spread to the lungs, liver or brain and produces very high hCG. It is treated with the multi-drug EMA-CO regimen, started gently in the sickest women to avoid early deaths, and most are cured; resistant disease gets platinum regimens, immunotherapy or surgery."@en ;
  schema:url <https://onco.cc/cancers/high-risk-gtn/> ;
  schema:dateModified "2026-09-18"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Choriocarcinoma> ;
  schema:citation <https://doi.org/10.1002/ijgo.13877>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1489>, <https://en.wikipedia.org/wiki/Choriocarcinoma> ;
  onco:tag "subtype-page", "gynaecologic" ;
  onco:related <https://onco.cc/cancers/low-risk-gtn/>, <https://onco.cc/cancers/placental-site-trophoblastic-tumour/>, <https://onco.cc/cancers/gestational-trophoblastic/>, <https://onco.cc/cancers/non-seminoma/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/ultrasound/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/ct/>, <https://onco.cc/technologies/pet-ct/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/technologies/serum-tumour-markers/> ;
  onco:targets <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/drugs/dactinomycin/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/avelumab/> ;
  onco:terms <https://onco.cc/terms/tumour-markers/>, <https://onco.cc/terms/staging-systems/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-bower-ema-co-high-risk-gtn-charing-cross-jco-1997/>, <https://onco.cc/key-papers/paper-figo-cancer-report-gestational-trophoblastic-disease-ijgo-2021/>, <https://onco.cc/key-papers/paper-figo-2000-staging-gestational-trophoblastic-neoplasia-ijgo-2002/> ;
  onco:pipeline <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/avelumab/> ;
  onco:standardOfCare <https://onco.cc/technologies/ct/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/ultrasound/>, <https://onco.cc/terms/tumour-markers/>, <https://onco.cc/terms/staging-systems/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/drugs/dactinomycin/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/avelumab/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/technologies/pet-ct/> .